InventisBio Co., Ltd
30
6
12
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
3.3%
1 terminated/withdrawn out of 30 trials
94.1%
+7.6% vs industry average
10%
3 trials in Phase 3/4
0%
0 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (30)
Healthy Volunteer Study
Role: lead
A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis
Role: lead
Mass Balance Study of [14C] D-2570
Role: lead
A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)
Role: lead
A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis
Role: lead
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
Role: lead
A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
Role: lead
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
Role: collaborator
Single and Multiple Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-2570 Tablets in Healthy Subjects
Role: lead
Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis
Role: lead
Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis
Role: lead
A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis
Role: lead
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
Role: lead
Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
Role: lead
Study to Evaluate D-1553 in Subjects With Solid Tumors
Role: lead
Study to Evaluate D-1553 in Subjects With Lung Cancer
Role: lead
A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer
Role: lead
A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553
Role: lead
Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients
Role: lead
D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer
Role: lead